All the news Showing 10 of 213 articles from: Pharmaceutical industryGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Gilead Sciences Returns to Growth in the First Quarter Motley Fool / 03 May 2019 NHS trumpets Hep C deal, quietly drops 2025 elimination target after legal row pharmaphorum / 30 April 2019 NHS England strikes world leading deal to help eliminate hepatitis C NHS England / 30 April 2019 Gilead experimental NASH drug fails another study Reuters / 29 April 2019 New “Generic” Naloxone: Expect More Big-Pharma Sleight of Hand Filter / 25 April 2019 Louisiana picks drug company for hepatitis C treatment plan San Francisco Chronicle / 27 March 2019 Interview With Charles Gore, Medicines Patent Pool Executive Director Intellectual Property Watch / 24 March 2019 With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition STAT / 19 February 2019 Malaysia Still Under Pressure To Make Hepatitis C Medicine More Expensive Intellectual Property Watch / 15 February 2019 Gilead’s Liver-Drug Setback Clouds $35 Billion Dream Bloomberg / 13 February 2019 ← Prev12345...22Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive